This is a single-patient extended access treatment protocol to be conducted in the United States. Investigator-Physician has determined patient satisfies expanded access inclusion criteria and has requested expanded access to tradipitant.~Patient will be given open label tradipitant 85 mg to be taken twice daily at 12 hour intervals for long term treatment. Patient can fill out daily web-based symptom diaries on a voluntary basis and report any adverse events to Investigator-Physician.~Primary Objective:~-To treat a single patient with gastroparesis who has requested expanded access with tradipitant~Secondary Objectives:~To monitor the efficacy of tradipitant in reducing individual symptoms associated with gastroparesis in this single patient~To monitor the safety of tradipitant in a patient with gastroparesis by assessing adverse events in this single patient
Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant